ProPharma Welcomes Dan Ryan as New President
ProPharma, a leader in regulatory and clinical services for the life sciences sector, has announced the appointment of Dan Ryan as President of Clinical Research Solutions (CRS). Dan brings nearly two decades of experience, enhancing ProPharma's ability to provide top-tier clinical trial management and support.
Dan Ryan's Expertise and Vision
With significant experience in oncology and hematology from his previous role at ICON, Dan has an impressive background. His leadership at G1 Therapeutics, Worldwide Clinical Trials, and Syneos Health positions him as a key addition to ProPharma's executive team. He possesses a deep understanding of the clinical trial landscape and will lead ProPharma's full-service clinical trials service line.
Enhancing Clinical Capabilities
Dan expressed enthusiasm about joining ProPharma, highlighting the company's unique capability to deliver operational excellence in a complex clinical environment. His insights will drive the expansion of clinical services, helping to accelerate the delivery of essential therapies globally.
Launch of FSP Solutions
In tandem with Dan's appointment, ProPharma has launched FSP (Functional Service Provider) Solutions. This new initiative supports the existing FSP services while expanding into regulatory affairs, pharmacovigilance, and quality assurance. Kevin Wysocki will lead this new division, further solidifying ProPharma's commitment to comprehensive clinical support.
Strategic Insights from Leadership
Jason DeGoes, President of ProPharma, emphasized the importance of Dan’s and Kevin’s combined expertise in navigating the growth dynamics of both CRS and FSP. This strategic evolution allows ProPharma to manage increasing demands in clinical trial management effectively.
About ProPharma
For over 25 years, ProPharma has empowered organizations in biotech, medical devices, and pharmaceuticals by providing expert guidance. This support helps clients advance scientific breakthroughs and introduce innovative therapies. With a suite of customizable consulting services, ProPharma mitigates risk and accelerates the development of high-profile drug and device programs.
About Odyssey Investment Partners
Odyssey Investment Partners is a renowned private equity firm with a strong track record of enhancing the performance of middle-market companies. With a focus on long-term growth, Odyssey partners with seasoned managers to transform businesses in favorable industry trends.
Frequently Asked Questions
Who is Dan Ryan in relation to ProPharma?
Dan Ryan is the newly appointed President of Clinical Research Solutions at ProPharma, bringing extensive experience in clinical trial management.
What is ProPharma known for?
ProPharma specializes in regulatory, clinical, and compliance services for the life sciences sector, helping organizations advance their scientific innovations.
What is the significance of the FSP Solutions launch?
The FSP Solutions initiative aims to enhance ProPharma's clinical support capabilities, including services in regulatory affairs and pharmacovigilance.
How does ProPharma approach clinical trials?
ProPharma focuses on delivering operational excellence and scientific rigor to ensure successful and timely clinical trials.
What company is behind ProPharma?
ProPharma is a portfolio company of Odyssey Investment Partners, which is a leading private equity investment firm.
